You just read:

New Janssen Phase 3 Data In Patients With Moderately To Severely Active Rheumatoid Arthritis Shows Sirukumab Significantly Inhibited Radiographic Progression And Improved Signs And Symptoms Of Disease

News provided by

Janssen Research & Development, LLC

Jun 08, 2016, 07:05 ET